Douglas Miehm
Stock Analyst at RBC Capital
(3.30)
# 1,012
Out of 5,241 analysts
65
Total ratings
52.08%
Success rate
3.72%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $252 → $262 | $213.21 | +22.88% | 10 | May 8, 2026 | |
| MNKD MannKind | Maintains: Sector Perform | $3.5 → $4.75 | $3.09 | +53.72% | 6 | May 7, 2026 | |
| PCRX Pacira BioSciences | Maintains: Sector Perform | $22 → $24 | $22.64 | +6.01% | 1 | May 1, 2026 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $10 → $9 | $5.42 | +66.05% | 22 | Apr 27, 2026 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $16.09 | +18.09% | 14 | Nov 14, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $15.28 | -1.83% | 11 | Nov 5, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.85 | +488.24% | 1 | Mar 10, 2025 |
Ligand Pharmaceuticals
May 8, 2026
Maintains: Outperform
Price Target: $252 → $262
Current: $213.21
Upside: +22.88%
MannKind
May 7, 2026
Maintains: Sector Perform
Price Target: $3.5 → $4.75
Current: $3.09
Upside: +53.72%
Pacira BioSciences
May 1, 2026
Maintains: Sector Perform
Price Target: $22 → $24
Current: $22.64
Upside: +6.01%
Bausch Health Companies
Apr 27, 2026
Maintains: Sector Perform
Price Target: $10 → $9
Current: $5.42
Upside: +66.05%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $16.09
Upside: +18.09%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $15.28
Upside: -1.83%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.85
Upside: +488.24%